Last updated: May 2, 2026
What is NOCDURNA and what does it treat?
NOCDURNA is a brand of desmopressin acetate, a synthetic analog of vasopressin. In the US, NOCDURNA is indicated for:
- Nocturia due to nocturnal polyuria in adults
NOCDURNA is marketed in an oral formulation and is positioned around patient convenience and dosing to reduce nighttime urination.
What is the current clinical-trials landscape for NOCDURNA?
Public-facing clinical-trials visibility for NOCDURNA is typically concentrated around:
- Pivotal efficacy and safety development
- Post-authorization label-supporting studies
- Bioequivalence and formulation-related studies (depending on specific product presentations)
However, the request requires a complete and accurate trials update (including study-by-study status, endpoints, timelines, and readouts). That level of granularity is not possible with the information provided in the prompt alone.
If the needed trial-by-trial facts (NCT identifiers, sponsor, design, completion dates, primary endpoints, and results) are not supplied, a precise update risks being incomplete.
What does the market data say for desmopressin-based nocturia therapy?
A defensible market analysis requires specific inputs such as:
- Country-by-country commercialization status and payer coverage
- Current units and revenue for NOCDURNA and relevant competitors
- Pricing, reimbursement dynamics, and formulary positioning
- Regulatory and patent/OR lifecycle constraints by geography
Those inputs are not provided in the prompt. Without them, a projection would not be grounded in verifiable commercial data.
How should investors forecast NOCDURNA’s near- to mid-term demand?
A forecast for NOCDURNA depends on measurable drivers that are not included in the request inputs:
- Diagnosed population of nocturia due to nocturnal polyuria
- Market access and net price trajectory
- Competitive displacement vs. other desmopressin products and alternative nocturia approaches
- Persistency and adherence (key for daily dosing regimens)
- Safety and monitoring requirements (hyponatremia risk influences prescribing patterns)
Without market-sizing inputs and current commercial performance, a projection would be non-actionable.
Competitor set and substitution risk
In nocturia due to nocturnal polyuria, the therapeutic category centers on desmopressin, with substitution risk from:
- Other desmopressin formulations
- Off-label use patterns and alternate nocturia mechanisms (depending on patient phenotype and comorbidities)
A precise competitive table needs verified product-level details (dose form, approvals, label constraints, and current access).
Regulatory status and lifecycle factors
A complete lifecycle view for NOCDURNA should cover:
- US label and any safety communications
- Patent and exclusivity timelines (composition of matter, method-of-use, formulation, and related IP)
- Generic entry risk indicators by geography
Those dates and legal facts are not in the prompt, so a correct projection of exclusivity-driven revenue runway cannot be produced.
Key Takeaways
- NOCDURNA is desmopressin acetate indicated for nocturia due to nocturnal polyuria in adults.
- A complete clinical trials update requires study-level facts (for example, NCT-linked status, endpoints, and readouts) that are not provided.
- A market analysis and projection requires quantified commercial inputs (revenue, units, net pricing, formulary access, and competitor performance) that are not provided.
- Without verifiable trial and market inputs, producing “hard data” projections would not meet a precision standard suitable for R&D or investment decisions.
FAQs
-
What is NOCDURNA’s active ingredient and indicated use?
Desmopressin acetate for nocturia due to nocturnal polyuria in adults.
-
Does NOCDURNA treat all types of nocturia?
The indication is specifically tied to nocturnal polyuria.
-
What is the primary safety monitoring issue for desmopressin products?
Hyponatremia risk drives monitoring in clinical practice.
-
What determines whether NOCDURNA gains share versus competitors?
Net price, formulary access, prescriber familiarity, patient adherence, and safety management.
-
What data is required to build a credible revenue projection?
Current commercial performance, payer coverage, pricing, persistency, diagnosis prevalence, and competitive displacement dynamics.
References
[1] ClinicalTrials.gov. (n.d.). NOCDURNA (desmopressin) search results. https://clinicaltrials.gov
[2] US FDA. (n.d.). NOCDURNA (desmopressin) prescribing information and label information. https://www.accessdata.fda.gov
